×
About 687 results

ALLMedicine™ T Cell Lymphomas Center

Research & Reviews  341 results

Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma.
https://doi.org/10.1080/14656566.2021.1882997
Expert Opinion on Pharmacotherapy; Wolska-Washer A, Smolewski P et. al.

Feb 1st, 2021 - Peripheral T cell lymphomas (PTCL) are a group of heterogenous hematologic malignancies derived from post-thymic T lymphocytes and mature NK cells. Conventional chemotherapy does not guarantee a good outcome. The article summarizes recent investig...

Pralatrexate for refractory mycosis fungoides in two Japanese patients.
https://doi.org/10.1111/1346-8138.15761
The Journal of Dermatology REFERENCES; Teraishi M, Oguro T et. al.

Jan 17th, 2021 - Pralatrexate has been approved for the treatment of relapsed/refractory peripheral T cell lymphomas. Studies in the U.S. also support the clinical efficacy of pralatrexate to treat advanced-stage cutaneous T-cell lymphomas, but outcomes in Japanes...

Novel targeted therapies of T cell lymphomas.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775630
Journal of Hematology & Oncology; Iżykowska K, Rassek K et. al.

Jan 1st, 2021 - T cell lymphomas (TCL) comprise a heterogeneous group of non-Hodgkin lymphomas (NHL) that often present at an advanced stage at the time of diagnosis and that most commonly have an aggressive clinical course. Treatment in the front-line setting is...

The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and tar...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897252
Journal of the American Academy of Dermatology; Durgin JS, Weiner DM et. al.

Dec 22nd, 2020 - Cutaneous T cell lymphomas (CTCLs) are malignancies of skin-trafficking T cells. Patients with advanced CTCL manifest immune dysfunction that predisposes to infection and suppresses the antitumor immune response. Therapies that stimulate immunity ...

Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-...
https://doi.org/10.1089/hum.2020.215
Human Gene Therapy; Choi S, Pegues MA et. al.

Dec 8th, 2020 - Chimeric antigen receptors (CARs) are artificial fusion proteins that incorporate antigen-recognition domains and T cell signaling domains. CD30 is a cell surface protein expressed on Hodgkin's lymphoma, some T cell lymphomas, and some B cell lymp...

see more →

Clinicaltrials.gov  343 results

Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma.
https://doi.org/10.1080/14656566.2021.1882997
Expert Opinion on Pharmacotherapy; Wolska-Washer A, Smolewski P et. al.

Feb 1st, 2021 - Peripheral T cell lymphomas (PTCL) are a group of heterogenous hematologic malignancies derived from post-thymic T lymphocytes and mature NK cells. Conventional chemotherapy does not guarantee a good outcome. The article summarizes recent investig...

Pralatrexate for refractory mycosis fungoides in two Japanese patients.
https://doi.org/10.1111/1346-8138.15761
The Journal of Dermatology REFERENCES; Teraishi M, Oguro T et. al.

Jan 17th, 2021 - Pralatrexate has been approved for the treatment of relapsed/refractory peripheral T cell lymphomas. Studies in the U.S. also support the clinical efficacy of pralatrexate to treat advanced-stage cutaneous T-cell lymphomas, but outcomes in Japanes...

Novel targeted therapies of T cell lymphomas.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775630
Journal of Hematology & Oncology; Iżykowska K, Rassek K et. al.

Jan 1st, 2021 - T cell lymphomas (TCL) comprise a heterogeneous group of non-Hodgkin lymphomas (NHL) that often present at an advanced stage at the time of diagnosis and that most commonly have an aggressive clinical course. Treatment in the front-line setting is...

The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and tar...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897252
Journal of the American Academy of Dermatology; Durgin JS, Weiner DM et. al.

Dec 22nd, 2020 - Cutaneous T cell lymphomas (CTCLs) are malignancies of skin-trafficking T cells. Patients with advanced CTCL manifest immune dysfunction that predisposes to infection and suppresses the antitumor immune response. Therapies that stimulate immunity ...

Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-...
https://doi.org/10.1089/hum.2020.215
Human Gene Therapy; Choi S, Pegues MA et. al.

Dec 8th, 2020 - Chimeric antigen receptors (CARs) are artificial fusion proteins that incorporate antigen-recognition domains and T cell signaling domains. CD30 is a cell surface protein expressed on Hodgkin's lymphoma, some T cell lymphomas, and some B cell lymp...

see more →

News  3 results

HDAC/HMA combo shows ‘remarkable’ activity in PTCL
https://www.mdedge.com/hematology-oncology/article/206189/t-cell-lymphomas/hdac/hma-combo-shows-remarkable-activity-ptcl?channel=303
Neil Osterweil

Aug 9th, 2019 - LUGANO, SWITZERLAND – A combination of 5-azacytidine and romidepsin showed promising activity in patients with peripheral T cell lymphomas, particularly angioimmunoblastic T-cell lymphoma (AITL) and primary cutaneous follicular helper T-cell lymph.

Treatment of Cutaneous T-Cell Lymphoma/Mycosis Fungoides
https://www.medscape.com/viewarticle/551357

Abstract and Introduction Abstract Cutaneous T cell lymphomas (CTCL) represent a heterogeneous group of T-cell malignancies that manifest primarily in the skin. By far the most common variant of CTCL is mycosis fungoides and its leukemic variant S...

see more →